VLST, Pfizer deal

Pfizer granted VLST worldwide rights to cancer compound CP-870,893. The anti- CD40 mAb has completed five Phase I trials. VLST expects to start additional Phase I testing in about 6-9 months to confirm dosing and safety information ahead of Phase II trials. Pfizer received an upfront payment, which includes a 5% stake in VLST, and is eligible for milestones, plus royalties. Additionally, the pharma retains co-exclusive rights in the cancer vaccine field. VLST declined to provide financial details, while Pfizer could not be reached. ...